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A universal anti-Xa assay for the determination of rivaroxaban, apixaban
and edoxaban drug concentrations would simplify laboratory procedures
and facilitate widespread implementation. Following two pilot studies ana-
lysing spiked samples and material from 698 patients, we conducted a
prospective multicentre cross-sectional study, including 867 patients treated
with rivaroxaban, apixaban or edoxaban in clinical practice to comprehen-
sively evaluate a simple, readily available anti-Xa assay that would accu-
rately measure drug concentrations and correctly predict relevant levels in
clinical practice. Anti-Xa activity was measured by an assay calibrated with
low-molecular-weight heparin (LMWH) in addition to ultra-high perfor-
mance liquid chromatography-tandem mass spectrometry (LC-MS/MS). As
an external validation, LMWH-calibrated anti-Xa activity was also deter-
mined in nine external laboratories. The LMWH-calibrated anti-Xa activity
correlated strongly with rivaroxaban, apixaban or edoxaban drug levels
[rs = 098, 95% confidence interval (CI) 098–098]. The sensitivity for the
clinically relevant cut-off levels of 30, 50 and 100 µg/l was 962% (95% CI
944–974), 964% (95% CI 944–977) and 967% (95% CI 943–981)
respectively. Concordant results were obtained in the external validation
study. In conclusion, a universal, LMWH-calibrated anti-Xa assay accu-
rately measured rivaroxaban, apixaban and edoxaban concentrations and
correctly predicted relevant drug concentrations in clinical practice.
Keywords: factor Xa inhibitors, rivaroxaban, apixaban, edoxaban, heparin,
low-molecular-weight, drug monitoring.
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Introduction
Rapid and accurate determination of anticoagulant drug
levels is essential in critical clinical situations such as urgent
surgery, planned thrombolysis or major bleeding.1 Any anti-
coagulation treatment is inevitably associated with an
increased risk of bleeding. This risk is as high as 15%/year in
certain patient populations.2,3 Besides, ~25% of intracranial
haemorrhages, which are the most dangerous adverse events,
are linked to anticoagulation treatment.4 The bleeding risk
associated with anticoagulants is particularly important in
trauma patients because uncontrolled bleeding is the leading
cause of death in these patients.5 In any patient with massive
bleeding, early and targeted treatment is the most critical
measure to save lives because 80% of trauma deaths occur
within the first hour after trauma.1,5,6 Laboratory tests that
can rapidly verify the presence of a relevant anticoagulant
drug level will support a fast treatment with reversal agents.1
Besides, knowledge of the anticoagulant drug level is essential
in case of urgent surgery and planned thrombolysis.7 Rapid
intervention is required in both cases, but an increased
bleeding risk exposes patients to high procedural risks. Thus,
simple laboratory tests that accurately determine the antico-
agulant drug level would improve care in patients with anti-
coagulation treatment.1
The proportion of the population taking direct oral antico-
agulants (DOACs) such as rivaroxaban, apixaban or edoxaban
is rapidly increasing and critical clinical situations occur fre-
quently.8,9 A simple and readily available laboratory test, accu-
rately determining these anticoagulants’ concentration in
various healthcare settings, would improve care in this vulner-
able population. Routine coagulation tests, which are widely
available, are not suitable for determining DOAC drug
levels.10–12 Anti-Xa assays, which are successfully used for the
monitoring of heparin and low-molecular-weight heparin
(LMWH)13 were introduced and a nice linear relationship was
demonstrated in samples spiked with rivaroxaban.14,15 DOAC-
calibrated anti-Xa activity correlated well with drug concentra-
tions if measured in healthy volunteers and even patients.11,16–
23 However, widespread implementation in clinical practice is
hampered by two major problems. First, a large study investi-
gating the accuracy of all Xa inhibitors over the full spectrum
of concentrations in clinical practice is still missing. Second,
providing different assays for the determination of rivaroxa-
ban, apixaban, and edoxaban drug levels in a ‘24/7’ service is
elaborate and expensive. It would be very convenient if labora-
tories could use a test that is already available in 24/7 service
to determine all three Xa inhibitors. Such a universal anti-Xa
assay for the determination of rivaroxaban, apixaban and
edoxaban drug levels would simplify laboratory procedures
and foster widespread implementation.
We hypothesised that a readily available LMWH-calibrated
anti-Xa assay would accurately measure rivaroxaban, apixa-
ban and edoxaban drug concentrations and correctly predict
relevant levels in clinical practice. In the present study, we




A phased approach was chosen to evaluate the universal test.
The sensitivity and linearity of measurements were studied in
spiking experiments. The feasibility of the test for the mea-
surement of rivaroxaban, apixaban and edoxaban was
observed in a retrospective analysis. The diagnostic accuracy
was tested in a large prospective cross-sectional study in clin-
ical practice. External validation in nine laboratories was
additionally conducted.
Pilot study: spiking experiments
Standardised human plasma (Cryocheck pooled normal
plasma, Precision Biologic, Dartmouth, Canada) was spiked
with increasing concentrations of rivaroxaban or apixaban
respectively. Stock solutions containing rivaroxaban and
apixaban were prepared using dimethylsulphoxide (DMSO)
following the manufacturer’s internal instructions. Seven
concentrations between 10 and 200 µg/l were prepared and
monitored using a drug-specific and drug-calibrated anti-Xa
assay (Biophen DiXaI, Hyphen BioMed, Neuilly-sur Oise,
France). Final DMSO concentrations were <1%. Rivaroxaban
and apixaban pure substances were provided by Bayer AG
(Wuppertal, Germany) and Bristol Myers Squibb Company
(New Brunswick, NJ, USA). Samples were snap-frozen at
80°C after preparation and sent on dry ice to seven spe-
cialised haemostasis laboratories. The LMWH-calibrated anti-
Xa activity was measured within 2 weeks using local reagents
and analysers (Biophen Heparin LRT on Sysmex CS5100,
Siemens BCS XP, or Stago STA-R evolution). Edoxaban pure
substance was not yet available at the time of the spiking
experiments.
Pilot study: retrospective analysis
In a retrospective analysis, laboratory data collected between
2014 and 2017 in one university hospital were retrieved.
During this period, drug-specific anti-Xa activity was mea-
sured once daily in batches, and LMWH-calibrated anti-Xa
activity was used as a proxy in 24/7 service. Inclusion criteria
were: (a) anti-Xa activity for rivaroxaban or apixaban
requested (edoxaban was not yet available), (b) age >18 years
and (c) signed general consent. An exclusion criterion was
the application of anticoagulants other than rivaroxaban or
apixaban. Venous blood was drawn into tubes containing
0109 M sodium citrate (BD Vacutainer, Plymouth, UK). A
standardised protocol was implemented to ensure adequate
pre-analytical conditions. Citrated samples were snap-frozen
at 80°C after determining LMWH-calibrated anti-Xa
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activity until analysis of drug-specific specific anti-Xa activity
(using rivaroxaban and apixaban calibrators). The LMWH-
calibrated anti-Xa activity was done using Biophen Heparin
LRT on a Sysmex CS5100 analyser. Drug-specific anti-Xa
activity was determined using Biophen DiXaI on a Siemens
BCS XP (Siemens Healthineers, Erlangen, Germany). Strict
management guidelines are implemented and the laboratory
is accredited to the Swiss Accreditation Service (SAS). The
appropriate Ethics Committee approved the study protocol
and all patients signed a general informed consent.
Cross-sectional study: design, setting and population
We conducted a prospective, multicentre cross-sectional
study to test the hypothesis that a LMWH-calibrated anti-Xa
assay would accurately measure rivaroxaban, apixaban and
edoxaban drug levels in clinical practice and correctly predict
clinically relevant concentrations. The flow chart of the
patients is given in Fig 1. Consecutive in- and outpatients
treated with rivaroxaban, apixaban or edoxaban in clinical
practice were included in 2018 and 2019 in nine major
haemostasis laboratories affiliated to Swiss tertiary hospitals.
Inclusion criteria were: (a) age >18 years, (b) use of rivaroxa-
ban, apixaban or edoxaban, (c) drug-level requested and (d)
signed general informed consent, if required by local authori-
ties. Exclusion criteria were: (a) refused general informed
consent, (b) additional use of heparin, (c) more than one
DOAC used, (d) pre-analytical issues and (e) insufficient
sample material. The appropriate Ethics Committee approved
the protocol and the study was conducted in accordance with
the declaration of Helsinki.
Ultra-high performance liquid chromatography-tandem
mass spectrometry (UPLC-MS/MS) targeting rivaroxaban,
apixaban, edoxaban and edoxaban M4 metabolite was con-
ducted as the reference standard in parallel to the LMWH-
calibrated anti-Xa assay at Inselspital, Bern University Hospi-
tal; details are discussed below. Clinically relevant drug con-
centrations were defined as 30, 50 and 100 mg/l.24
To determine the limit of detection (LOD), 20 blank sam-
ples were determined on 20 consecutive days.25 Samples with
low drug concentration (~80 µg/l) and high drug concentra-
tion (200 µg/l) were measured 15 times to determine the
within-run imprecision and on 15 consecutive days to verify
the day-to-day imprecision.
External validation
As an external validation, the LMWH-calibrated anti-Xa
measurements were conducted in nine referring laboratories
using the same sample for the cross-sectional study men-
tioned above. We aimed to confirm the applicability of the
specific cut-offs to other laboratories. Measurements were
conducted after inclusion, but before freezing the samples.
Local reagents and analysers established for the determina-
tion of LMWH drug levels were utilised. The following
reagents and analysers were used: Biophen Heparin LRT on
a Sysmex CS-5100 (four laboratories), Biophen Heparin
LRT on a BCS XP (Siemens Healthineers; one laboratory),
Biophen Heparin LRT on an ACL Top 750 (Instrumenta-
tion Laboratory; two laboratories), STA-LIQUID anti-Xa on
a STA-R (Stago; one laboratory), and HemosIL liquid anti-
Xa on ACL Top 750 (one laboratory).
Data collection and handling of samples
Anonymised data were collected in a password protected
RedCAP database. The following data were retrieved: age, sex
and drug. Samples were de-identified before shipment. Pro-
tocols ensuring adequate pre-analytical conditions were
implemented at all institutions.26 Briefly, venous blood was
drawn in plastic syringes containing 1 ml trisodium citrate
(0106 or 0109 mol/l respectively) per ml of blood. Citrated
samples were collected with a different syringe to avoid tissue
factor contamination. Tourniquet application was limited to
a minimum and removed before blood withdrawal. Samples
were transported and processed immediately. After aliquot-
ing, samples were snap-frozen at 80°C and shipped on dry
ice in one batch to the central laboratory (delivery time 3–
4 h). Samples were stored continuously at 80°C until test-
ing without any freeze–thaw cycle. The storage period varied
between 1 and 13 months. Laboratory test results were
exported automatically to avoid typing errors.
Determination of the universal anti-Xa assay
Concluding from the two pilot studies and previous
research, we selected the Biophen Heparin LRT with
LMWH calibrators.14,16 This assay is implemented in many
Swiss institutions for the determination of LMWH drug
levels.13 All analyses were conducted in batches on an Atel-
lica COAG 360 analyser (Siemens Healthineers).27 A five-
step calibration curve with the following concentrations of
LMWH was applied: 00, 042, 086, 126 and 167 iu/ml
(Biophen Heparin Calibrator). Samples were rapidly
thawed and gently mixed at 37°C. The patient’s plasma was
pre-diluted (1/2; 100 µl) and added to the solution contain-
ing the chromogenic substrate (250 µl). Factor Xa (250 µl)
was added after incubation at 37°C. The reaction was
stopped after 120 s and the absorption was measured at
405 nm. All instructions of the manufacturers were strictly
followed. Following these instructions, the maximum level
was 334 iu/ml. Clinical information and reference standard
test results were not available to the performer of the anti-
Xa assay.
Determination by LC-MS/MS
The LC-MS/MS was conducted to quantify rivaroxaban,
apixaban, edoxaban and edoxaban M4 metabolite. For pro-
tein precipitation and analyte extraction, 10 µl acetonitrile:
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water 1:1 (v/v), 25 µl extraction buffer (MassTox TDM Ser-
ies A, Chromsystems Instruments and Chemicals GmbH,
Gr€afelfing, Germany) and 240 µl precipitation reagent (Mas-
sTox TDM Series A, Chromsystems Instruments and Chemi-
cals) containing the internal standards (rivaroxaban 13C6,
apixaban 13C,D3 and edoxaban 13C,D2) were added to
50 µl plasma. After vortexing, the samples were centrifuged
at 14 000 g and 20°C for 4 min. A 20-µl aliquot of the
supernatant was diluted with 80 µl of water:methanol 8:2 (v/
v) and stored at 10°C until analysis. Calibrators and quality
controls were prepared in pooled plasma (Innovative
Research, Novi, MI, USA); 3 µl of the extracted samples were
analysed by reversed-phase chromatography (Cortecs UPLC
C18 column, 21 9 75 mm, 17 µm; Waters Corp., Milford,
MA, USA) on a triple quadrupole mass spectrometer (Xevo
TQ-S, Waters) coupled to a UPLC Acquity I-Class system
(Waters). Rivaroxaban, apixaban, edoxaban and edoxaban
M4 were separated at 04 ml/min with a gradient using water
(A) and methanol (B) acidified with 01% (v/v) formic acid
as mobiles phases (00–05 min, 20% B; 05–25 min, 20–
99% B; 25–35 min, 99% B; 35–351 min, 99–20% B; 351–
45 min, 20% B). The source offset and transition parameters
were optimised for each analyte. The raw data were pro-
cessed with TargetLynx available in the MassLynx software
(version 4.1, Waters). Edoxaban M4 metabolite was summed
with edoxaban for further analysis. Rivaroxaban, apixaban
and edoxaban pure substances were provided by Bayer AG,
Bristol Myers Squibb Company and Daichi Sankyo Co, Ltd.
(Tokyo, Japan). Clinical information and index test results
were not available to the performer of the LC-MS/MS.
Statistical analysis
Descriptive statistics were used to describe the study popu-
lation (numbers, percentages, or median and range, as
appropriate). The Spearman correlation coefficient was cal-
culated to determine the level of agreement between the
universal anti-Xa assay and the LC-MS/MS. Spearman cor-
relations of ≥090 were regarded as high.16 A modified
Bland–Altman plot was obtained to determine a possible
systematic bias over the measurement range (ratios rather
differences were used to account for different scales). Dem-
ing regression was additionally calculated. Sensitivities and
specificities were calculated regarding the clinically relevant
Fig 1. Flow of the patients. A prospective, multicentre cross-sectional study was conducted to test the hypothesis that a universal anti-Xa assay
would accurately measure rivaroxaban, apixaban, or edoxaban drug levels in clinical practice, and correctly predict clinically relevant drug levels.
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drug concentrations of 30, 50 and 100 mg/l.24 The corre-
sponding cut-off points of the universal anti-Xa assay were
determined using Deming regression. Sensitivity and speci-
ficity >90% was regarded as high.16 The LOD was calcu-
lated in 20 blank samples (3 9 standard variation) and the
coefficient of variation (SD/mean) in 15 measurements of
samples with low and high drug concentrations (within-run
and day-to-day imprecision).25 We conducted a power anal-
ysis for a one-sample correlation test. A power of 09 and
an alpha level of 005 was applied. We further considered
that a sufficient number of patients should be distributed
among the full range of measurements. However, as long as
many patients were taking rivaroxaban and apixaban, and
only a few patients edoxaban, patients’ inclusion was con-
tinued until 932 patients were included. Analyses were per-
formed using the Statistical Package for the Social Sciences
(SPSS) version 24 (IBM Corp., Armonk, NY, USA) and
Stata version 14.1 (Stata Corp LP, College Station, TX,
USA). Figures were created using Prism 8 (GraphPad Soft-
ware, Inc., La Jolla, CA, USA).
Results
Spiking experiments
Calculated and realised concentrations of the spiked samples
are shown in Table SI of the supplemental material. Figure 2
illustrates the association between LMWH-calibrated anti-Xa
measurements and drug concentrations in all seven laborato-
ries. The Spearman correlation coefficient between anti-Xa
activity and drug concentrations was 10 in all laboratories.
Retrospective analysis
A total of 698 samples from 474 patients were available for
analysis. Among them, 432 patients were taking rivaroxaban
and 73 apixaban. The median (range) age was 682 (18–
99) years and 701% were female. The correlations between
LMWH- and drug-calibrated anti-Xa activities are shown in
Figure S1 of the supplemental material. The Spearman corre-
lation coefficient was 096 for rivaroxaban [95% confidence
interval (CI) 095–097] and 098 for apixaban (95% CI
097–099). A deviation from linearity was observed in
patient samples >483 µg/l.
Patient characteristics
A total of 932 patients were included in nine study centres
(Fig 1). In all, 35 patients were excluded because of heparin
use, two were excluded because more than one DOAC was
used, five were excluded due to pre-analytical issues, and 23
were excluded due to insufficient sample material. Thus, 867
patients were eventually available for analysis. Among those,
375 patients were taking rivaroxaban, 426 apixaban and 66
edoxaban. The median [interquartile range (IQR)] age was
76 (66–82) years and 428% of the patients were female.
Rivaroxaban, apixaban and edoxaban drug levels were bal-
anced distributed over the full range of measurements
(Fig 3).
Diagnostic accuracy
The association between measurements of the LMWH-cali-
brated anti-Xa assay and drug concentrations is shown in
Fig 3. The Spearman correlation coefficient rs was 099 for
rivaroxaban (95% CI 098–099), 097 for apixaban (95% CI
096–097) and 098 for edoxaban (95% CI 095–099). Below
50 µg/l, the rs was 090 (95% CI 088–093) and above
200 µg/l, the rs was 080 (95% CI 074–086). Above 483 µg/l,
the rs was 040 and the association was not linear anymore
(Fig 3).
The slope of the regression equation was 0012 for
rivaroxaban (95% CI 0011–0013), 0011 for apixaban (95%
CI 0010–0012) and 0010 for edoxaban (95% CI 0008–
0013). The y-intercept was 0006 (rivaroxaban, 95% CI
0025 to 0011), 0050 (apixaban, 95% CI 0015 to 0084)
and 0001 (edoxaban, 95% CI 0037 to 0034).
The diagnostic accuracy of the LMWH-calibrated anti-Xa
assay against the clinically relevant drug concentrations is
illustrated in Fig 4. Drug levels of >30 µg/l were detected
with a sensitivity of 962% (95% CI 944–974; cut-off value
035 u/ml), drug levels of >50 µg/l with a sensitivity of
964% (95% CI 944–977; cut-off value 058 u/ml) and drug
levels of >100 µg/l with a sensitivity of 964% (95% CI 940–
979; cut-off value 114 u/ml). The specificities were 929%
(95% CI 889–955), 933% (95% CI 901–955) and 920%
(95% CI 894–940) respectively. The area under the receiver-
operating characteristic (ROC) curve (AUC) was 099 for all
three cut-offs.
The LOD was 1485 µg/l, the within-run imprecision was
14 [coefficient of variation (CV)], and the day-to-day
imprecision 21 (CV). No differences were observed in sam-
ples with ≥6 months of storage time compared with samples
with <6 months storage time.
External validation
A total of 666 measurements were available for the external
validation (rivaroxaban, n = 322; apixaban, n = 289; edoxa-
ban, n = 55), results are shown in Fig 5. Correlation with
the drug level (rs) was 096 for rivaroxaban (95% CI 095–
097), 095 for apixaban (95% CI 094–096) and 097 for
edoxaban (95% CI 095–098). Drug levels of >30 µg/l were
detected with a sensitivity of 958% (95% CI 930–973),
drug levels of >50 µg/l with a sensitivity of 974% (95% CI
954–986) and drug levels of >100 µg/l with a sensitivity of
948% (95% CI 914–971). The specificities were 859%
(95% CI 803–902), 917% (95% CI 878–944) and 925%
(95% CI 894–949) respectively. The AUC was 098 for all
cut-offs.
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Discussion
In a comprehensive set of evaluation studies, a universal
LMWH-calibrated anti-Xa assay accurately estimated concen-
trations of rivaroxaban, apixaban and edoxaban, and cor-
rectly predicted relevant drug levels. We demonstrated a
sensitive and linear relationship between drug concentrations
and the assay measurements in spiking experiments. In an
extensive retrospective analysis, we confirmed the method’s
feasibility by comparing drug-specific measurements with
LMWH-calibrated results. A large prospective multicentre
cross-sectional study utilising LC-MS/MS as a reference stan-
dard established a high accuracy and sound sensitivity and
specificity for clinically relevant thresholds. Also, external val-
idation conducted in nine laboratories confirmed that the
assay can be applied to other institutions.
A few preliminary studies proposing a single calibration to
determine all anti-Xa inhibitors have been conducted; our
present results are essentially consistent with those results. A
high level of correlation was observed in a retrospective study
measuring an LMWH-calibrated assay and LC-MS/MS in
210 patients taking rivaroxaban or apixaban.28 Similar results
Fig 2. Low-molecular-weight heparin (LMWH)-calibrated anti-Xa activity in standardised plasma samples spiked with rivaroxaban, and apixaban,
as measured in seven haemostasis laboratories. Results of pilot study 1 are shown; Spearman correlation coefficient was 10 in all laboratories.
Fig 3. Measurements of a universal, low-molecular-weight heparin (LMWH)-calibrated anti-Xa assay in relation to drug concentrations in a mul-
ticentre cross-sectional study conducted in clinical practice (n = 867). Drug concentrations were determined using ultra-high performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Of the patients, 375 were taking rivaroxaban, 426 apixaban and 66 edoxaban. Spear-
man correlation coefficient was 099 for rivaroxaban (95% CI 098–099), 097 for apixaban (95% CI 096–097), and 098 for edoxaban (95% CI
095–099). [Colour figure can be viewed at wileyonlinelibrary.com]
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(A) (B)
(C)
Fig 4. Diagnostic accuracy of a universal, low-molecular-weight heparin (LMWH)-calibrated anti-Xa assay for the measurement of rivaroxaban,
apixaban, and edoxaban drug concentrations as determined in a multicentre cross-sectional study in clinical practice (n = 867). (A) Box plots
illustrating the distribution of measurements (median, interquartile range, minimum to maximum, all results) at clinically relevant cut-offs (>
and < 30, 50, and 100 µg/l). (B) Receiver-operating characteristic (ROC) curves showing the diagnostic accuracy. The area under the ROC curve
was 099 for all cut-offs. (C) Confusion matrices at each cut-off. Drug levels of >30 µg/l were detected with a sensitivity of 962% (95% CI 944–
974; cut-off value 035 u/ml), drug levels of >50 µg/l with a sensitivity of 964% (95% CI 944–977; cut-off value 058 u/ml) and drug levels of
>100 µg/l with a sensitivity of 964% (95% CI 940–979; cut-off value 114 u/ml). The specificities were 929% (95% CI 889–955), 933% (95%
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Fig 5. Results of an external validation of a universal, low-molecular-weight heparin (LMWH)-calibrated anti-Xa assay for the measurement of
rivaroxaban, apixaban, and edoxaban (n = 666). (A) Box plots illustrating the distribution of measurements (median, interquartile range, mini-
mum to maximum, all results) at clinically relevant cut-offs (> and < 30, 50, and 100 µg/l). (B) Receiver-operating characteristic (ROC) curves
showing the diagnostic accuracy. The area under the ROC curve was 098 for all cut-offs. (C) Confusion matrices at each cut-off. Drug levels of
>30 µg/l were detected with a sensitivity of 958% (95% CI 930–973), drug levels of >50 µg/l with a sensitivity of 974% (95% CI 954–986),
and drug levels of >100 µg/l with a sensitivity of 948% (95% CI 914–971). The specificities were 859% (95% CI 803–902), 917% (95% CI
878–944) and 925% (95% CI 894–949), respectively. [Colour figure can be viewed at wileyonlinelibrary.com]
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were also reported by a retrospective analysis by Douxfils
et al.18 in 52 patients and another cross-sectional analysis in
30 patients.29 More recently, rivaroxaban and apixaban-cali-
brated anti-Xa measurements were compared with possible
LMWH-calibrated measurements as inferred from the same
measurement.30 In addition, in vitro or ex vivo spiking exper-
iments have been done by several other authors, reporting
correlation coefficients ranging between 098 and 100.14,15,31
However, these studies’ methodology is limited by the num-
ber of participants, the choice of the reference standard, the
retrospective design, the range of measurements or the selec-
tion of drugs.
Our present study’s strength is that we have conducted a
comprehensive set of evaluation studies that were carefully
designed, thus clarifying all essential questions associated
with the implementation. In particular, the cross-sectional
study was prospectively designed and conducted in a multi-
centre design, including many patients. LC-MS/MS was uti-
lised in all patients as the most valid reference standard.
Moreover, a clinical practice rather than an artificial study
setting was chosen. External validation was done as well,
confirming the potential application of the specific cut-offs
to other laboratories.
The present study has several potential limitations. First,
edoxaban was not studied in the spiking experiments and the
retrospective analysis because it was not yet available in
Switzerland at the time of these experiments. As long as the
accuracy of the measurements was equivalent to rivaroxaban
and apixaban in the cross-sectional study and the external
validation, we believe that findings inferred from spiking
experiments and retrospective analysis can be extrapolated to
edoxaban as well. Second, the number of patients taking
edoxaban was limited because of its limited use in Switzer-
land. However, we estimate the risk of bias as low because
the accuracy measures are consistent between drugs and in
the external validation study. Third, one particular LMWH-
calibrated assay was studied and it might be possible that
other anti-Xa assays behave differently. Thus, these results
cannot straightforwardly be applied to other LMWH-cali-
brated anti-Xa assays. Fourth, external validation focussed on
the applicability of the specific cut-offs to other laboratories,
rather than the applicability to different patient populations.
However, we studied a large and diverse population, making
relevant differences unlikely.
How should the universal assay be applied? Two different
options appear feasible and are illustrated in Table I. First,
cut-off values for the clinical thresholds 30, 50 and 100 µg/l
can be given. The corresponding categorical result is the
most crucial information, which might directly prompt clini-
cal decision making. Second, the regression equations can be
used to determine drug levels as accurate as possible.
Our present findings confirm that LMWH-calibrated anti-
Xa assays can be used as a universal anti-Xa assay to deter-
mine rivaroxaban, apixaban and edoxaban drug concentra-
tions in clinical practice. Even though a high accuracy was
observed at all clinically relevant cut-offs, a wider spread and
a non-linear curve was observed in samples with high drug
levels. The reason for this effect was the maximum level,
which can be measured with the LMWH-calibrated assay
(334 u/ml corresponding to a drug level of 483 µg/l).
Although this effect will not alter most clinical decisions,
drug levels might be underestimated in case of intoxications
and accumulation. However, LMWH-calibrated assays might
not only simplify laboratory procedures and save healthcare
costs; it might foster the implementation of anti-Xa assays in
a variety of institutions. However, whether this universal
assay can be implemented for the determination of DOAC
drug levels depends on national in vitro diagnostics (IVD)
regulations and potential Conformite Europeene (CE) label-
ling of the manufacturer. In our laboratory, we implemented
it as a laboratory-developed in-house test.
Rapid determination of DOAC drug levels is essential in
critical clinical situations such as significant bleeding, urgent
surgery or planned thrombolysis.1 Given that the proportion
of patients with DOAC is rapidly increasing worldwide, uni-
versal anti-Xa assays have the potential to improve care in
many patients and various healthcare settings. Future
research shall confirm our observations in different health-
care settings, patient populations and using other LMWH-
calibrated assays. While LC-MS/MS is expensive and might
not be available in certain institutions, drug-specific anti-Xa
assays or even the Biophen Heparin LRT can be utilised as
a surrogate reference standard as well.
Conclusion
In conclusion, a universal LMWH-calibrated anti-Xa assay
accurately measured concentrations of rivaroxaban, apixaban
and edoxaban and correctly predicted relevant drug levels in
clinical practice. A sensitive and linear relationship was estab-
lished, the feasibility confirmed, a high accuracy and sound
sensitivity and specificity demonstrated and the test verified
in an external validation. Implementation of the universal
assay might not only simplify laboratory processes and save
Table I. Application of the low-molecular-weight heparin (LMWH)-
calibrated, universal assay.
Measure Result
DOAC cut-off value 30 µg/l 035 U/ml
DOAC cut-off value 50 µg/l 058 U/ml
DOAC cut-off value 100 µg/l 114 U/ml
Regression equation rivaroxaban 120 9 [U/ml]19
Regression equation apixaban 115 9 [U/ml]22
Regression equation edoxaban 164 9 [U/ml]24
Two options appear. First, cut-off values for the clinical thresholds
can be given. The corresponding categorial result is the most crucial
information, which can prompt clinical decision making. Second, the
regression equations can be used to calculate plasma concentrations
of the individual drugs.
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healthcare costs, but foster implementation of anti-Xa assays
for the determination of rivaroxaban, apixaban and edoxaban
in various healthcare settings. Future research shall confirm
our observations in other settings using different reagents
and analysers.
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Fig S1. Association of low-molecular-weight heparin
(LMWH)-calibrated and drug-specific anti-Xa activity mea-
surements in 698 patients taking rivaroxaban or apixaban.
Results of a retrospective analysis conducted in one Univer-
sity hospital are shown (pilot study 2). Spearman correlation
coefficient was 096 in case of rivaroxaban [95% confidence
interval (CI) 095–097] and 098 in case of apixaban (95%
CI 097–099).
Fig S2. A modified Bland–Altman plot using ratios to
determine a possible systematic bias over the measurement
range.
Table SI. Calculated and realised concentrations of spiked
samples. Concentrations were measured using a drug-specific
anti-Xa assay (Biophen DiXaI, Hyphen BioMed, Neuilly-sur
Oise, France).
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